OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear

800 Projects | 551 Researchers | $379,142,183 Invested

2025

Monash University

Joanne Ryan, PhD

Leveraging a large scale randomized clinical trial to determine whether statins can prevent Alzheimer’s Disease neuropathology and dementia

  • Funding Amount: $424,461
  • Organization Type:
  • Program: Prevention
  • Target: Vascular
  • Status: Active

2025

Emory University

Thomas Kukar, PhD

Development of a granulin biologic to treat progranulin deficient FTD.

  • Funding Amount: $349,890
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Proteostasis
  • Status: Active

2025

Foundation for the National Institutes of Health, Inc.

Tatiana Lagos

Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression

  • Funding Amount: $50,000
  • Organization Type:
  • Program: Biomarkers
  • Target: Neuronal Degeneration
  • Status: Active

2025

Circular Genomics Inc

Nikolaos Mellios, MD, PhD

Alzheimer’s disease specificity and sensitivity analyses of circRNA blood biomarkers

  • Funding Amount: $250,000
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2025

University of Gothenburg

Henrik Zetterberg, MD, PhD

Quality control (QC) program for CSF and plasma biomarkers for Alzheimer’s disease

  • Funding Amount: $1,999,997
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2025

Sunbird Bio

Mario Morken, MS/MBA

Proof-of-Principal clinical study for blood based extracellular vesicle bound biomarker signatures quantifying brain alpha synuclein aggregation state

  • Funding Amount: $249,887
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Target: Synuclein
  • Status: Active

2025

Banner Health

Nicholas Ashton, PhD

Determining %p-tau217 and MTBR-243 by immunoassay

  • Funding Amount: $250,000
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2024

MoCA Cognition

Ziad Nasreddine

Scientific validation of a digital MoCA for use in the general practice

  • Funding Amount: $1,036,093
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active

2024

Johns Hopkins University

Philip Wong, PhD

Develop a diagnostic biomarker for frontotemporal dementia.

  • Funding Amount: $640,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: TDP-43
  • Status: Active

2024

Alamar Biosciences

Xiao-Jun Ma, PhD

Development of ARGO DX™ for a new generation of blood-based diagnostics for Alzheimer’s disease and related neurodegenerative diseases

  • Funding Amount: $10,016,094
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active
View More